Approximately 2.5 billion cases of diarrhoea were noted worldwide in 2004, which results in 1.5 million deaths among children under the age of five. Greater than half of these were in Africa and South Asia. This is decreased from a death rate of 5 million per year two decades ago. Diarrhoea remains the second leading cause of death (16%). Since ancient time a number of herbal medicines have been used in place of synthetic drug due to its side effects.Mucosa capsule consists of A.marmelos, B.aristata, T. foenum gracum, P. granatum, H. rosa sinensis, P. longifolia. Mucosa and developed capsule had exhibited significant dose dependent Anti- Diarrhoeal and Antioxidant activities conforming the indication of the formulation. The established parameters can be utilized for maintaining uniform quality, purity, efficacy and safety of the Mucosa capsule.

Colorectal cancer is second leading cause of deaths in the United States. Various approaches available for The poor site specificity of pH dependent systems, because of large variation in the pH of gastrointestinal tract, was well established. The timed-release systems release their load after a predetermined period of administration. These are designed to resist the release of the drug in stomach and small intestine and release of the drug takes place in colon. Methotrexate (MTX) is a used in the treatment of colon cancer and now a days rheumatic disease. MTX is a folate antimetabolite. MTX has since been used in the treatment of various malignancies including osteosarcoma, non-Hodgkin's lymphoma, Hodgkin's disease, cutaneous T cell lymphoma, lung cancer, colon cancer and breast cancer. The conventional dosage forms which are used for colorectal cancer normally dissolve and absorbs in the stomach and small intestine; thus a very less quantity of dose of drug reaches to colonic region. Aim of present work is to develop and characterize colon targeted tablet of MTX for for treatment of colorectal cancer using different polymer and excipient by compression coating technology.

The aim of present research work is to develop single pulse pulsatile release tablets that release Lornoxicam instantly after the lag time of about 5 hour which can be used for treatment of rheumatoid arthritis where symptoms are at their prime in the morning hours. Such a pulsatile release tablet of Lornoxicam taken at bed time and release the drug in early morning, thus enhance patient compliance. From various approaches erodible compression coating system is selected for the formulation of pulsatile release tablets, in which outer coating containing mixture of hydrophilic polymer (sodium alginate) and hydrophobic polymer (ethylcellulose). The release profile of compression coated tablet exhibited lag time followed by burst release, in which outer shell break into two halves.

In past statistic formulation optimized by response surface methodology (RSM) is one of the techniques that have been employed to develop and formulate controlled release dosage forms but limitations to the RSM technique another technique called artificial neural networks (ANN) has recently gained wide popularity in the development of controlled release dosage forms. In this review articles most powerfully technique ANN has been optimized the formulation in controlled release drug delivery systems. The theory of arti cial neural networks is brie y reviewed focusing on supervised and unsupervised techniques which have great impact on current pharmaceutical applications. The basic ANN structure, Learning Laws, Network architectures and generalized distance function method to development of the ANN model and an explanation of how to use ANN to design and develop controlled release drug delivery systems are discussed. Overall the use of ANN offers a new dimension to pharmaceutical systems study because of its unique advantages, such as nonlinear processing capacity and the ability to model poorly understood systems.

The use of polymeric matrix devices to control the release of variety of therapeutic agents has become increasingly important in development of the modified release dosage forms. The device may be a swellable, hydrophilic monolithic systems, an erosion controlled monolithic system or a non erodible system. The initial burst release of 5-Fluoruracil from such matrix tablet surface can be controlled by compression coating technology. Appropriate combination of hydrophilic polymer in upper and lower layer of tablet can govern the release of 5-fluoruracil as well as lag time to deliver it in effective concentration to the colon with reduced toxicity. The lag time can be controlled by appropriate combination of polymer and excipients in coating layer. The release mechanism of 5-fluoruracil from the compression coated tablets was controlled by the rate of water uptake into the core tablet, which in turn was dependent upon the channeling agent used, the type and concentration of polymer. The hydration and swelling of these polymers results in the formation of gel which control the release of 5-fluoruracil from tablet.

Various approaches have been paused to increase the duration of oral dosage form in the stomach, including floating systems, swelling and expanding system, modified shape system, high density systems and other delayed gastric emptying devices. (Magnetic systems, Super porous -biodegradable hydrogel systems). Hydrodynamically balanced systems (HBS) -incorporated buoyant materials enable the device to float. Raft systems incorporate alginate gels - these have a carbonate component and, upon reaction with gastric acid, bubbles form in the gel, enabling floating. Swelling type of dosage form are such that after swelling, this product swell to extent that prevent their exit from the stomach through the pylorus. As, a result, the dosage form retained in the stomach for a longer period of time. These systems may be referred to as a "Plug type system," since they exhibit tendency to remain logged in the pyloric sphincters.

Dissolution is important parameter to achieve desired concentration of drug in systemic circulation for elicit pharmacological response. The formulation of poorly soluble drugs has been the subjects of much research, as approximately 40% of new chemical entities develop in pharmaceutical industries are insoluble in nature. In the present investigation drugs which are practically insoluble in gastric fluid and having high permeability through stomach were selected. The rational for selecting such type was "Drugs which are only permeable through stomach but due to its solubility limitation in gastric fluid they can not enter in to systemic circulation, further more gastric empting time is ranging form 30 mins to 2 hrs after this time drugs enter in to small intestine where they can soluble but can not permeable through its membrane due to its permeation limitation." To improve dissolution of such drugs in stomach are challenging and rational. Attempts were made to prepare formulations which would dissolved completely within 30 minutes or retain in stomach for more than 2 hrs if drugs can not soluble in 2 hrs even after addition of solubilising enhancing excipients.